The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Updated efficacy and safety of JNJ-5322, a next-generation trispecific antibody, in R/R myeloma
Amrita Krishnan, MD, City of Hope, Duarte, CA, shares updated efficacy and safety results from a Phase I study (NCT05652335) evaluating JNJ-5322 (romantamig), a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Krishnan notes that the data remain promising and that the agent offers the benefit of convenient administration in the outpatient setting. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
